These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8371131)

  • 1. Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.
    Pavone-Macaluso M; Tripi M; Ingargiola GB; Corselli G; Pavone C; Serretta V
    J Chemother; 1993 Jun; 5(3):207-11. PubMed ID: 8371131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
    Shuin T; Kubota Y; Noguchi S; Hosaka M; Miura T; Kondo I; Fukushima S; Ishizuka E; Furuhata A; Moriyama M
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S52-6. PubMed ID: 7994787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
    Eto H; Oka Y; Ueno K; Nakamura I; Yoshimura K; Arakawa S; Kamidono S; Obe S; Ogawa T; Hamami G
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S46-51. PubMed ID: 7994786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
    van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R;
    J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin: a review of its intravesical use in superficial bladder cancer.
    Onrust SV; Wiseman LR; Goa KL
    Drugs Aging; 1999 Oct; 15(4):307-33. PubMed ID: 10582777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
    Hinotsu S; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Matsumura Y; Niijima T; Obata K; Ohashi Y; Ohe H; Shimazaki J; Tashiro K;
    Gan To Kagaku Ryoho; 2002 Jan; 29(1):73-80. PubMed ID: 11816482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
    Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
    Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
    Uekado Y; Hirano A; Shinka T; Ohkawa T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group.
    Shinohara N; Nonomura K; Tanaka M; Nagamori S; Takakura F; Seki T; Koyanagi T; Togashi M; Maru A
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S41-5. PubMed ID: 7994785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor--prophylactic and therapeutic instillation for carcinoma in situ].
    Shichiri Y; Kanba T; Yoshida S; Arai Y
    Hinyokika Kiyo; 1995 May; 41(5):359-64. PubMed ID: 7598036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
    Raitanen MP; Lukkarinen O
    Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
    Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.
    van der Meijden AP; Kurth KH; Oosterlinck W; Debruyne FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S95-8. PubMed ID: 1394828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
    Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
    Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.